Updated: Oct 5, 2019
On Sep 27th, 2019, Mr. Chuck Clarvit, Advisor of Bridge Point Capital, and Mr. Mark Young, Co-founder and Managing Partner of Bridge Point Capital, were invited to speak at 2019 SAPA Annual Conference.
The Sino-American Pharmaceutical Professionals Association (SAPA) is one of the most active and influential Chinese professional associations in the US with 6000+ members who are primarily from multi-national pharmaceuticals, biotech companies, government regulators, law firms and investment companies. The 2019 annual conference mainly focused on the highlights of recent pharmaceutical R&D, regulatory policies, investment opportunities and future development trends. The attendees include giant pharmaceutical companies such as Merck, Novartis, Bristol-Myers Squibb and etc., top scientists such as 2018 Nobel Laureate in Chemistry Martin Chalfie, advisors from U.S. Food and Drug Administration, and prestigious institutional investors including AIG and Fosun.
During the investment summit section, Mr. Chuck Clarvit presented on a subject that really captivated the audience - Investment Strategies for Institutional Investors Focused on the Healthcare Industry. On the basis of his many successful investments in the past, Mr. Clarvit shared his unique insights on the healthcare industry, and talked about how to properly identify the value and risks of target companies. Mr. Clarvit, before being known as a well reputed investor, used to at IBM and BlackRock as a senior executive. Currently Mr. Clarvit sits on the Board of Trustees of Johns Hopkins University and is managing his own family office - Clarvit Capital Family Office (CCFO). He officially joined the Advisory Board of Bridge Point Capital in May 2019.
In addition, Mr. Chuck Clarvit and Mr. Mark Young attended the healthcare investment elite forum, a section specifically designed for investment professionals to discuss latest industry trends and opportunities. Mr. Young gave an overview of the recent milestones in Sino-US healthcare industry and forecasted the future of the sector based on China-US relationship and related policies. Regarding the policy barriers faced by Chinese companies on either their US investments or licensing advanced techniques back to China, Mr. Clarvit inspired the audience with new strategies under the current policy trends of Committee on Foreign Investment in the United States (CFIUS) and U.S. Food and Drug Administration (FDA).
Bridge Point Capital is a private equity firm based in New York with a focus on U.S.-China cross-border investment. We invest in disruptive late-stage healthcare companies that can benefit from penetrating the vast, yet unexplored, Chinese healthcare market. We aim to leverage our expertise in both healthcare and capital markets to provide the best investment platform we possibly can for our investors.